Listed

Design Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2021

Filed with the SEC on Mar 10, 2022 and accepted by EDGAR at Mar 10, 2022, 16:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2021-01-01 to 2021-12-31$24.8mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-01-01 to 2021-12-31−$35.8mus-gaap:OperatingIncomeLoss
Net income12 months2021-01-01 to 2021-12-31−$35.5mus-gaap:NetIncomeLoss
Operating cash flow12 months2021-01-01 to 2021-12-31−$29.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$1.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-12-31$298.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$385.4mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$390.6mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$5.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$8.4mus-gaap:Liabilities
Shareholders' equityAt period end2021-12-31$382.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-003369. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.